We invest in founders shaping the future of health care.
Alleviant Medical is focused on developing a novel minimally-invasive device to treat congestive heart failure. Our proprietary technology is designed to relieve heart failure symptoms, improve quality of life, and reduce hospital admissions for over 16 million patients currently suffering from this disease in the US and EU.
Babyscripts’ market-leading pregnancy app is your digital front door to engage and remotely monitor pregnant & postpartum patients.
Briteseed is commercializing a new class of smart surgical tools that have artificial-vision assistance to help surgeons quickly identify landmarks and safely navigate vital structures. These multifunctional tools have the benefit of cautery, dissection, and optical tissue sensing in a single package.
CNSDose uses advanced genetic technology to fast-track finding the right antidepressant and dose. Genetically guided prescribing via CNSDose results in a 2.5 times greater likelihood of remission, which means faster recovery, reducing suffering and cutting costs that result from trial-and-error prescribing.
CorInnova is developing a soft robotic heart assist device that gently squeezes the heart in synchrony with the heartbeat to increase output. Delivered minimally invasively, the device is designed to bring a new paradigm of treatment to the 95 percent of heart failure patients who are ineligible for existing cardiac devices.
Deep 6 AI finds more, better matching patients for clinical trials in minutes rather than months by using artificial intelligence on clinical data.
At Ictero Medical, we are developing the CholeSafe System, the first minimally invasive treatment option that helps decrease complications and costs while providing definitive therapy to high risk surgical patients with gallstone disease. Unlike laparoscopic cholecystectomy, the CholeSafe System can be used in the interventional radiology suite with only minimal local anesthesia to defunctionalize the gallbladder without having to remove it. This allows providers to give their patients the benefits of surgery, without the risk.
Intelligent Implants is a bioelectronics company developing a revolutionary electrical stimulation platform technology that is incorporated into standard-of-care orthopedic implants. Its first product, SmartFuse, represents a novel method of delivering electric current to aid spinal fusion that can induce, direct, and monitor bone growth in real-time.
LumaHealth’s cloud-based platform empowers healthcare providers with HIPAA-compliant, mobile-first SMS and secure chat communication tools that enable frictionless patient-provider conversations — including intelligent scheduling, referral management, actionable reminders, and care pathway messaging.
Medable is transforming healthcare by providing an enterprise platform for “Direct-to-Patient” clinical care and clinical trials, enabling patient generated data to drive healthcare delivery, research, and personalized and predictive medicine.
MIC is a software company that provides real time patient monitoring and predictive analytics across the continuum of care in the hospital. Its innovative SickbayTM platform archives, aggregates, and transforms short-lived, high-resolution waveform data across disparate devices to enable anywhere, anytime remote monitoring. MIC applies machine learning to develop predictive algorithms, laying the groundwork for future AI-based solutions that predict patient risk and deterioration and enable data-driven medicine and patient-centered care.
NarrativeDx uses AI to identify actionable insights from patient and provider feedback that improves patient satisfaction scores, increases operational efficiency and decreases employee turnover.
Full details on the 2020 acquisition here.
Noninvasix will be the first company to non-invasively monitor the severity of sepsis and septic shock, enabling clinicians to diagnose and monitor the response to treatment of tissue hypoxia in real-time. Noninvasix’s patented optoacoustic platform technology is the first solution to non-invasively and continuously measure central venous saturation. Incorporating Noninvasix into the ICU workflow allows clinicians to more quickly and accurately diagnose their critically ill patients and tailor treatments to improve outcomes. Future developments, enhancements and evidence will expand the use and clinical impact of our technology into other indications and settings.
Sonavex’s two FDA approved products, EchoMark and EchoSure, enable ultrasound based vascular monitoring to detect flow compromises earlier.
Trusted Health is an opportunity platform for the modern nurse, connecting top RNs to flexible nursing jobs at innovation employers.
Volumetric, Inc. was founded in 2018 by Jordan Miller and Bagrat Grigoryan. Our mission is to empower the next generation of advanced biofabrication with high quality materials and systems for 3D bioprinting.
Full details on the 2021 acquisition here.
